December 16, 2025 8:06am

A Humpty-Dumpty, Capricor Therapeutics (CAPR) closed up +$0.53 after Friday -$1.16 after Thursday’s -$1.49, Wednesday’s +$1.29, Tuesday’s -$1.18 and last Monday’s +$1.67.  With more down side (-$) to follow! <see The Bottom Line>

Pre-open Signals: 1 Negative Indications, I'll admit to

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t! 

 

The peril facing the cell and gene therapy (C&GT) sector’s share pricing isn’t just applications of macro or even micro econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data.

Monday’s RMi Closing Bell: Suck it up … https://www.regmedinvestors.com

 

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is pumping the volume and share pricing? … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The pre-open Dow futures are DOWN -0.03% or (-14 points), the S&P futures are OWN -0.07% or (-4 points) and the Nasdaq futures are DOWN -0.12% or (-31 points)

  • Stock futures are faking awaiting econs, Tuesday, 12/16
  • European markets slid,
  • Asia Pacific markets losses were everywhere

 

Economic data reporting: November nonfarm payrolls figures are set for release Tuesday, along with October retail sales figures.

  • November’s jobs report, which will be out Tuesday morning, could be a catalyst for stocks. Economists polled by Dow Jones predict that nonfarm payrolls grew by 45,000, down sharply from the 119,000 jobs added in September. They also see the unemployment rate coming in at 4.5%, compared to the rate of 4.4% in September. October’s retail sales report is also due.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed DOWN -41.31 points or -0.09%, the S&P closed DOWN -10.90 points or -0.16 % while the Nasdaq closed DOWN -137.757 points or -0.59%
  • Friday: The Dow closed DOWN -245.96 points or -0.51%, the S&P closed DOWN -73.59 points or -1.07% while the Nasdaq closed DOWN -398.686 points or -1.69%
  • Last week: The S&P 500 is down -0.6%, the Dow is up +1% and the Nasdaq is -1.6%.
  • The previous week: The S&P 500 is up +0.3%, the Dow +0.5% and the Nasdaq is up +0.9%.
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 4 positive and 7 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

I resisting and restricting my comments, not seeing any postentials, ough CAPR is STILL on my NAUGHTY list

 

 

The BOTTOM LINE: Still feeling the what … anxiety with a small dose/feeling of optimism!

Maintaining MY opinion, conviction - (also a play-on-words from title): Capricor Therapeutics (CAPR) is overvalued, overbought and headed to a BIG slide … I would also ask if the SEC should investigate the post news run-up and the sudden offering financing pricing … 12/2 pricing, $6.36, offering price of $25.00 to Friday’s $26.55?

With NO indication this a.m. …

Not anyone else is on the same page:

  • Remaining risks are tied to HOPE-3 and potential priority review dynamics
  • Make your own decision to CUT-BACK as regulatory moving pieces will shape the investment narrative
  • Investors may wish to stay informed to better track and interpret future shifts in CAPR's soon to be evolving story – can you afford to wait and possibly take a hit out-of-the-blue.

Welcome to my world of defining the “grey’ in our universe!

  • With a downside end-of-month and year rotation and rebalance, In the last of December and 2025, it means investors have to be careful of slippage targets.

 

Current week;

  • 12/15 – Monday closed negative with 15 positive, 23 negative and 2 flats

Last week:

  • 12/15 – Monday closed negative  with 15 incliners, 23 decliners and 2 flats
  • 12/12 – Friday closed negative with 12 positive, 26 negative and 2 flats
  • 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
  • 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
  • 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

!'st week of December:

  • 12/5 – Friday closed negative with 13 positive, 26 negative and 1 flat
  • 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
  • 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.